CL2020001464A1 - Péptidos antimicrobianos y métodos para usarlos. - Google Patents

Péptidos antimicrobianos y métodos para usarlos.

Info

Publication number
CL2020001464A1
CL2020001464A1 CL2020001464A CL2020001464A CL2020001464A1 CL 2020001464 A1 CL2020001464 A1 CL 2020001464A1 CL 2020001464 A CL2020001464 A CL 2020001464A CL 2020001464 A CL2020001464 A CL 2020001464A CL 2020001464 A1 CL2020001464 A1 CL 2020001464A1
Authority
CL
Chile
Prior art keywords
methods
antimicrobial peptides
peptides
antimicrobial
x9cyx10x11
Prior art date
Application number
CL2020001464A
Other languages
English (en)
Inventor
Christopher A Zook
Michael Kuhn
Derek James Sheehan
Eric Baima
Richard Andrew Ewin
Hilary Phelps
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2020001464A1 publication Critical patent/CL2020001464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8281—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for bacterial resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)

Abstract

Se proporcionan péptidos antimicrobianos de la fórmula general X0X1X2C X3X4X5CX6X7X8 X9CYX10X11 CX12X13. También se proporcionan ciertas formulaciones que contienen estos péptidos y métodos de uso de estos péptidos para tratar infecciones cutáneas en un animal que lo necesita.
CL2020001464A 2017-12-07 2020-06-02 Péptidos antimicrobianos y métodos para usarlos. CL2020001464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762595725P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
CL2020001464A1 true CL2020001464A1 (es) 2020-11-06

Family

ID=65003464

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001464A CL2020001464A1 (es) 2017-12-07 2020-06-02 Péptidos antimicrobianos y métodos para usarlos.

Country Status (27)

Country Link
US (3) US11352396B2 (es)
EP (2) EP4656726A3 (es)
JP (1) JP7381465B2 (es)
KR (3) KR102555177B1 (es)
CN (1) CN111479824A (es)
AR (1) AR113618A1 (es)
AU (3) AU2018378035B2 (es)
BR (1) BR112020009973A2 (es)
CA (1) CA3082491A1 (es)
CL (1) CL2020001464A1 (es)
CO (1) CO2020006907A2 (es)
DK (1) DK3720875T3 (es)
ES (1) ES3041688T3 (es)
FI (1) FI3720875T3 (es)
HU (1) HUE072916T2 (es)
IL (2) IL275074B2 (es)
LT (1) LT3720875T (es)
MX (1) MX2020005920A (es)
NZ (1) NZ764838A (es)
PH (1) PH12020550942A1 (es)
PL (1) PL3720875T3 (es)
PT (1) PT3720875T (es)
SG (1) SG11202004661QA (es)
SI (1) SI3720875T1 (es)
TW (2) TWI786887B (es)
WO (1) WO2019113181A1 (es)
ZA (1) ZA202003387B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220307048A1 (en) * 2021-03-23 2022-09-29 Genvor Inc. Antimicrobial peptides
CN113185576B (zh) * 2021-04-09 2023-05-30 倪京满 一类具有RRRF转角的β-发卡型低毒广谱抗菌肽及其应用
US20250042946A1 (en) 2021-12-08 2025-02-06 Oakgrove Bio Llc Biological Production of Histidine-Rich Peptides
EP4198045A1 (en) * 2021-12-16 2023-06-21 Université de Lille Antimicrobial peptides, variants and chemical analogues thereof and their uses
WO2024003890A1 (en) * 2022-06-29 2024-01-04 Omnix Medical Ltd. Novel peptide for treating an infectious disease or condition
CN120309697B (zh) * 2025-06-13 2025-09-02 四川大学 一种用于抗革兰氏阴性菌的多肽药物及应用
CN121378418B (zh) * 2025-12-26 2026-04-03 四川大学 一组针对革兰氏阴性菌的抗菌多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323166C (zh) * 2003-09-18 2007-06-27 中国农业科学院饲料研究所 一种鲎素的基因及表达其的方法
CN101307316B (zh) * 2008-07-22 2011-03-16 北京中农颖泰生物技术有限公司 抗菌肽cad在枯草杆菌中的分泌表达及重组枯草杆菌表达系统
CN101698682B (zh) * 2009-10-26 2012-05-23 陕西省微生物研究所 一种基于抗菌肽的双功能融合蛋白及其制备方法和用途
CN101817883B (zh) * 2010-03-12 2012-06-13 广东药学院 一种家蝇天蚕素-人溶菌酶融合蛋白及其制备方法和应用
CN101851620B (zh) * 2010-04-21 2012-05-23 吉林农业大学 利用食药用菌生产FGFs的方法
CA2890357C (en) * 2011-07-13 2024-01-09 Solarvest BioEnergy Inc. Methods and uses of a modified cecropin for treating endoparasitic and bacterial infections
CN104177502B (zh) * 2014-08-21 2018-04-24 天津兰瑞生物技术有限公司 一种鲎素肽-抗体融合蛋白及制备方法
CN104988170B (zh) * 2015-08-01 2018-01-16 吉林农业大学 一种融合抗菌肽及其制备方法和应用

Also Published As

Publication number Publication date
TWI746908B (zh) 2021-11-21
PH12020550942A1 (en) 2021-05-10
US20200385429A1 (en) 2020-12-10
ES3041688T3 (en) 2025-11-13
US20250074947A1 (en) 2025-03-06
EP3720875A1 (en) 2020-10-14
BR112020009973A2 (pt) 2020-11-03
PT3720875T (pt) 2025-09-18
SI3720875T1 (sl) 2025-11-28
TW202116348A (zh) 2021-05-01
KR20240151857A (ko) 2024-10-18
CO2020006907A2 (es) 2020-06-19
EP4656726A2 (en) 2025-12-03
AU2023229465B2 (en) 2024-06-13
TW201924712A (zh) 2019-07-01
FI3720875T3 (fi) 2025-09-12
HUE072916T2 (hu) 2025-12-28
US11352396B2 (en) 2022-06-07
NZ764838A (en) 2023-07-28
JP2021505624A (ja) 2021-02-18
CN111479824A (zh) 2020-07-31
AU2018378035B2 (en) 2023-06-15
IL275074A (en) 2020-07-30
KR102555177B1 (ko) 2023-07-12
TWI786887B (zh) 2022-12-11
TW202204376A (zh) 2022-02-01
ZA202003387B (en) 2023-01-25
CA3082491A1 (en) 2019-06-13
AU2024219645A1 (en) 2024-10-03
PL3720875T3 (pl) 2025-10-20
AR113618A1 (es) 2020-05-20
EP3720875B1 (en) 2025-07-16
RU2020118460A (ru) 2022-01-10
IL312730A (en) 2024-07-01
AU2023229465A1 (en) 2023-09-28
JP7381465B2 (ja) 2023-11-15
RU2020118460A3 (es) 2022-01-10
KR20230110822A (ko) 2023-07-25
KR102713813B1 (ko) 2024-10-11
IL275074B1 (en) 2024-06-01
US20230077604A1 (en) 2023-03-16
LT3720875T (lt) 2025-08-25
AU2018378035A1 (en) 2020-05-28
SG11202004661QA (en) 2020-06-29
WO2019113181A1 (en) 2019-06-13
MX2020005920A (es) 2020-08-20
DK3720875T3 (da) 2025-09-01
US12054518B2 (en) 2024-08-06
KR20200074212A (ko) 2020-06-24
IL275074B2 (en) 2024-10-01
EP4656726A3 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MX374365B (es) Extracto de algas para su uso en calidad de agente inmunomodulador.
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
MX391040B (es) Formulacion de alta concentracion.
MX2018013409A (es) Métodos y dispositivos para la preparación de agentes de contraste de ultrasonido.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MX391757B (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX392976B (es) Composiciones que comprenden cepas bacterianas.
EA202091456A1 (ru) Мононитрат моноацетата пропандиола
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения